Great. Missling and Anavex need Ihub...
...to learn how to run the business. The real experts are here.
A number of people have replicated the same form of mistake several investment advisors have made, in summary, this.
Billions of dollars have been spend by many big pharmaceutical companies trying to prove (in FDA-authorized clinical trials) that their drugs would treat or cure Alzheimer's by removing beta-amyloid and tau tangle waste proteins from nerves. Every one of these attempts has been a dismal failure. Therefore, Anavex 2-73 is likewise destined for a company-killing clinical failure.
The other perspective is, simply, small pharmaceutical start-ups almost universally fail. Therefore, so will Anavex Life Sciences Corp.
It's called extrapolation, the extending of generalized information from earlier events to new ones in the future. All were failures in the past; therefore all of those failures, of every form (bad management, failed trials, etc.) necessarily extrapolate to young, new-technology companies like Anavex Life Sciences Corp.
If posters are certain of either of these outcomes, it can be questioned as to why such critics post here. Perhaps, so laudably, cautionary postings regarding AVXL equity purchases are intended to be helpful, keeping ignorant blokes from being caught up in the not-yet-proven Anavex science, saving those unfortunates a lot of money to be lost. All well and good, another direction of the due diligence that equity purchases suggest.
There are other reasons negative, cautionary postings might appear. I'll let the reader discern those (should they actually apply).
There are for me (and I believe most here) two essential differences with Anavex Life Sciences Corp. First, this is in no way a typical, hard to survive pharmaceutical start-up. The experiences and qualifications of officers and scientists equal (or exceed) those of any Big Pharma company. Many millions of dollars in Anavex bank accounts, too.
Secondly, the company's proprietary disease treatment molecules are in no way in the same class or have cellular or chemical mechanisms of action of the numerous Alzheimer's drug failures.
Apples and oranges in both cases. Extremely competent and experienced management, and revolutionary drug molecules unlike any others, which will change 21st-century medicine more than antibiotics did in the last century.
